出生后右心室容积超负荷小鼠模型的建立与确认
2023年6月9日
1.7K 次观看
该方案介绍了腹动静脉瘘（AVF）小鼠出生后右心室容积超负荷（VO）模型的建立和确认，该模型可用于研究VO如何促进出生后心脏发育。
我们的研究范围是先天性心脏病和心脏再生。我们试图了解容量或压力超负荷如何影响出生后的心肺发育，包括心肌细胞增殖和成熟。我们已经开发了各种类型的先天性心脏病出生后小鼠或大鼠模型。
例如，心室超负荷、压力超负荷和肺血流量减少。这些模型令人着迷，将促进我们对小儿先天性心脏病的理解。几十年来，AVF模型一直被用于诱导成年动物的慢性心脏VO。
然而，人们对出生后小鼠的模型知之甚少。本研究通过创建腹部 AVF 生成了 VO 出生后小鼠模型。证明了右心室的形态学和血流动力学变化。
查看完整文字稿并访问数千部科学视频
概述
本协议介绍了腹部动静脉瘘（AVF）小鼠出生后右心室容量超负荷（VO）模型的建立和确认，可用于研究VO如何影响出生后心脏发育。
关键研究组成部分
科学领域
- 先天性心脏病
- 心脏再生
- 出生后心脏发育
背景
- 了解容量或压力超负荷对心脏和肺部发育的影响。
- 开发各种出生后小鼠或大鼠先天性心脏病模型。
- 使用AVF模型在成年动物中诱导慢性心脏VO。
- 对出生后小鼠中AVF模型的知识有限。
研究目的
- 研究容量超负荷如何影响出生后心脏发育。
- 加深对儿科先天性心脏病的理解。
- 为未来的研究建立可靠的模型。
使用的方法
- 建立出生后右心室容量超负荷模型。
- 确认模型的有效性。
- 应用该模型研究心脏发育。
- 在小鼠中使用腹部动静脉瘘（AVF）。
主要结果
- 在出生后小鼠中成功建立了容量超负荷模型。
- 了解VO对心脏发育的影响。
- 进一步研究儿科心脏病的潜力。
- 为理解先天性心脏病机制做出贡献。
结论
- AVF模型是研究出生后心脏发育的宝贵工具。
- 容量超负荷对儿科人群的心脏健康有重大影响。
- 需要进一步研究VO的长期影响。
常见问题
AVF模型的意义是什么？
AVF模型有助于理解出生后小鼠的慢性心脏容量超负荷，这对于研究先天性心脏病至关重要。
容量超负荷如何影响心脏发育？
容量超负荷可能导致心肌病，并影响出生后发育期间心脏细胞的增殖和成熟。
这项研究的潜在应用是什么？
这项研究可以推进儿科先天性心脏病的知识，并为治疗策略提供信息。
为什么出生后建模很重要？
出生后建模使研究人员能够在接近人类条件的环境中研究心脏发育。
这项研究的下一步是什么？
未来的研究将探索容量超负荷对心脏功能和发育的长期影响。
Executive Industry Relevance
Establishing a postnatal right ventricular volume overload (VO) mouse model enables mechanistic de-risking of pediatric congenital heart disease targets and pathways. This model provides predictive confidence for early-stage discovery by recapitulating disease-relevant hemodynamic stress in a controlled, reproducible system. Its integration supports translational continuity from target validation through preclinical assessment in pediatric cardiovascular research portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of developmental cardiac response to VO for target validation.
- Supports mechanistic de-risking by modeling pediatric-specific myocardial adaptation.
- Facilitates portfolio triage by clarifying pathway relevance in congenital heart disease.
Screening & Assay Development
- Provides a validated in vivo system for quantitative assessment of cardiac remodeling.
- Enables standardization of echocardiographic and hemodynamic readouts for assay development.
- Supports reproducible evaluation of candidate interventions targeting VO-induced pathology.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints for pediatric heart failure and remodeling.
- Enables continuity from discovery through preclinical validation of therapeutic hypotheses.
- Supports risk-adjusted advancement decisions by modeling clinically observed RV changes.
Pipeline & Workflow Integration
This model positions within the early discovery to preclinical continuum, enabling hypothesis testing, target validation, and translational assessment of cardiac interventions in pediatric settings.
- Discovery Biology: Supports hypothesis testing on VO-induced cardiac remodeling and developmental adaptation.
- Screening: Provides quantitative, reproducible echocardiographic and hemodynamic outputs for assay readiness.
- Analytics: Delivers standardized measurements of RV morphology, stroke volume, and pressure for comparative analysis.
- Translational Research: Models disease-relevant endpoints for preclinical continuity in pediatric heart disease.
- Enterprise Reuse: Offers a reusable in vivo platform for cross-program cardiac research and target evaluation.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in pediatric cardiac target validation.
- Operational Value: Enables standardized, scalable, and reproducible in vivo modeling of VO.
- Strategic Value: Improves go/no-go decisions and capital efficiency by clarifying early-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of pediatric cardiovascular programs.
Implementation Considerations
- Requires expertise in microsurgical AVF creation and pediatric mouse handling.
- Needs access to high-resolution ultrasound and echocardiography instrumentation.
- Demands cross-team standardization of measurement protocols and data analysis.
- Adaptation may be needed for different developmental stages or genetic backgrounds.
- Model fidelity depends on consistent confirmation of VO status and fistula patency.
Biopharma FAQs
Why does null hypothesis testing matter for AVF-induced VO target validation?
Null hypothesis testing in the AVF-induced VO model enables objective assessment of whether observed cardiac changes are attributable to volume overload rather than procedural artifacts, supporting robust target validation in pediatric heart disease research.
How does independent variable isolation fit the echocardiographic workflow?
Isolating the variable of VO through controlled AVF creation and confirmation by ultrasound ensures that downstream echocardiographic measurements reflect true physiological remodeling, enhancing discovery-stage data integrity.
What do quantitative dependent variable measurements enable in this model?
Quantitative measurements such as RV stroke volume, cavity size, and systolic pressure provide actionable endpoints for comparing intervention effects and enable cross-study reproducibility in preclinical cardiac research.
Why are replication requirements critical for cross-functional collaboration?
Replication of AVF patency and VO confirmation across cohorts ensures that findings are robust and transferable, facilitating collaboration between discovery, translational, and preclinical teams.
What statistical analysis capabilities are required before model implementation?
Statistical analysis must support comparison of hemodynamic and morphological endpoints, including group means and variability, to validate model consistency and inform go/no-go decisions in R&D pipelines.
